[
    "{\"step_by_step_thinking\": \"Document [0] states that ocrelizumab significantly reduced the risk of disability progression in patients with primary progressive multiple sclerosis (PPMS). Document [1] also mentions that ocrelizumab has been approved as a treatment for primary progressive MS in adults. Document [2] further supports this by stating that ocrelizumab demonstrated efficacy in the treatment of PPMS. Document [3] also mentions that ocrelizumab reduced measures of clinical and MRI progression in patients with PPMS. Document [4] states that ocrelizumab is the first drug that has been shown to be able to significantly slow disability progression in patients with PPMS. All these documents provide evidence that ocrelizumab is effective for primary progressive multiple sclerosis.\", \"answer_choice\": \"A\"}"
]